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ABSTRACT  
Moxifloxacin (MOX) is a fluoroquinolone anti-infective drug, indicated for the treatment of bacterial conjunctivitis. The drug is soluble in water 
but still produces low ocular bioavailability due to biological barriers and so it requires dosing for two/three times a day. The present study 
was designed to formulate, optimize and characterize polymeric Nanoparticles MOX for ocular administration using Ion Exchange Resin (IER). 
IER-nanoparticles were prepared by media milling method, formulation/process parameters were optimized based on evaluation parameters 
such as color of nanosuspension, sedimentation behaviour, particle size and zeta potential. MOX-IER nanosuspensions were prepared at 
different stoichiometric ratio of MOX and IER and characterized by entrapment efficiency, pH, particle size and zeta potential of 
nanosuspension. In vitro release study of optimized batch MNIER3 exhibited sustained release pattern which follows Korsmeyer-Peppas model 
with Fickian diffusion mechanism for drug release. Based on these results optimized batch of MOX-IER nanosuspension formulated in the 
laboratory was found suitable for ocular delivery. 
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INTRODUCTION 
Infectious diseases are one of the strongest reasons of deaths 
in the world due to antibiotic resistance and chemical 
limitations on synthesis of the new antibiotic molecules,[1,2]. 
Bacterial conjunctivitis which is prevalent in patients of all 
ages is a common health-care issue for the general 
practitioner and the ophthalmologist. It is an inflammation of 
the conjunctiva caused by bacteria. In majority clinical cases 
the cause is Staphylococcus, Streptococcus, Haemophilus and 
Moraxella strains. Typical symptoms include red eye/ pink 
eye, mucous and pus discharge persistent throughout the 
day, pain and itching. Bacterial conjunctivitis can be 
contracted directly from infected individuals or can result 
from abnormal proliferation of the native conjunctival 
flora[3]. Phramacological treatments of Bacterial 
conjunctivitis include Aminoglycosides, Bacitracin, 
Polymyxin B Combinations, Fluoroquinolones and Macrolide 
antibiotics in the ascending order of choice [4]. In general 
Aminoglycosides are used as first line of treatment and 
Macrolide antibiotics are considered as the last line of 
treatment. 
Moxifloxacin is a 4th generation fluoroquinolone anti-
infective indicated for the treatment of bacterial 
conjunctivitis with good ocular penetration and potency 
against gram positive bacteria[5] Moxeza® and Vigamox® 
are the commercially marketed products, Eye drops 
containing Moxifloxacin ophthalmic solution dosed 2 to3 
times a day [6,7].Moxifloxacin is soluble in water. Due to 
various biological barriers in Ocular drug delivery [8,9,10,11] 
like (a) drug dilution on the precorneal tear film and rapid 
renewal rate of lachrymal fluid and blinking reflex (b) 
systemic drug absorption (c) rapid drug drainage from the 
site of application (d) lacrimation (e) aqueous humor 
drainage (f) corneal diffusion barrier, topically administered 
drugs are reaching in low concentration to the target site in 
the eye. Water soluble drugs are rapidly drained from the 
site of action. The unmet need is to develop topical 
formulation with sustained drug release effect which 
ultimately reduced dosage frequency also. 
Colloidal drug carriers have significant technological and 
therapeutic advantages in ophthalmic therapy with respect 
to conventional aqueous eye drops like increase in 
precorneal drug retention time, sustained drug release, 
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reduction in administration frequency, reduced drug toxicity, 
and targeted delivery to specific eye tissues [12,13,14,15]. 
Polymeric nanoparticles are one of the promising 
formulations for ophthalmic delivery using various polymers 
such as Ethyl cellulose and Eudragit [16], Chitosan, Sodium 
alginate, Poly-ε-caprolactone, Poly-L-lactide, and Poly-D, L-
lactide-co-glycolide [17,18]. Nanoemulsions using isopropyl 
myristate and triacetin have also been explored for 
ophthalmic application [19]. Nanoparticles form cross-linked 
collagen shields have been prepared and characterized for 
sustained delivery of drug after topical ophthalmic 
application[20]. Lipid nanoparticles [21], Lipid-polymer hybrid 
nanoparticles [22], Human serum albumin nanoparticles [23] 
have also been studied. Liposomes[24,25]and Microemulsions 
[26] have been developed for ophthalmic delivery. 
In current study, nanoparticles using Ion Exchange Resin 
(IER) were prepared. IER are polymers containing 
appropriately substituted acidic groups, such as carboxylic 
and sulfonic for cation exchangers; or basic groups, such as 
quaternary ammonium group for anion exchangers. IER 
forms complex with acidic and basic both type of drugs 
because they are in ionized form. Drug-IER complexes are 
insoluble in water and tend to release the drug from 
exchange of bound drug ions by ions normally present in 
body fluids[27,28] . Traditionally IER is utilized for taste 
masking and sustained drug release in oral formulations 
[29,30,31,32,33].IER is enormously used in variety of drug 
delivery systems [34 such as adhesive in conjugation with 
nanoparticles for subcutaneous delivery [35], dental 
adhesive[36] and ocular sustained drug release[37].  Drug-IER 
complex suspension is approved and commercially available 
in US market for ophthalmic delivery as Betoptic S®[38]. 
Aim of the present study is formulation of Moxifloxacin-IER 
complex nnanoparticles, optimization of (formulation and 
process) parameters and characterization of nanosuspension 
followed by evaluation of In vitro drug release behaviour to 
assess the scope of reducing the dosage frequency.Materials 
and Methods 
MATERIALS AND METHODS 
Moxifloxacin Hydrochloride was obtained as gratis sample 
from Torrent Pharmaceuticals Ltd. (Ahmedabad, India). 
Sodium polystyrene sulfonate, Ion Exchange Resin (IER) was 
a gift from DOW Chemicals (Mumbai, India). Yttirum 
stabilized Zirconium beads (Zirmil® Y, 0.3 mm and 0.8 mm) 
were received as a kind gift from Saint Gobain (Magnus 
Impex Private Ltd., New Delhi, India). Cerium stabilized 
Zirconium beads (Zirconox®, 0.7-1.2 mm & 1.2-1.7 mm) were 
purchased from Jyoti Ceramic (Nashik, India). Dialysis 
membrane (12000 M.W.C.O., DM-70) was obtained as a gift 
from Hi Media (Mumbai, India). All other chemicals like 
Sodium chloride, Sodium bicarbonate and Calcium chloride 
were of analytical grade. Freshly prepared distilled water 
was used to prepare formulations. Sieve of 250 micron, 
ASTM Mesh #60 was purchased from Wire Metal GMP 
Products, Mumbai, India. 
Drug characterization 
Solubility: According to Literature [39], Moxifloxacin 
Hydrochloride is soluble in water. Solubility study was 
performed by dissolving one unit of drug in one unit of 
solvent. Initially 1 mg of drug was dissolved in 1 ml of water 
at room temperature, 20-25°C. After this, if drug was 
completely dissolved, then more amount of drug was added. 
If not so, then more amount of solvent is added. Solution was 
then kept for 24 h to check re-precipitation at room 
temperature, 20-25°C[40]. 
Spectrophotometric analysis: Solution of Moxifloxacin 
Hydrochloride prepared in distilled water was run in UV 
Visible Spectrophotometer (Shimadzu, UV-1700 
PharmaSpec, Kyoto, Japan) from 200 to 400 nm to estimate 
wavelength at which maximum drug absorbance is noted. At 
maximum wavelength Standard Calibration Curve was 
prepared by preparing drug solutions of suitable 
concentrations in distilled water. 
Drug-IER compatibility 
Physical mixture of Drug and IER in 1:1 stoichiometric ratio 
was prepared and MOX content was estimatedafter 
incubation of 1 month accelerated stability at 40°C ± 2°C and 
75 %RH ± 5 %RH in accordance with International 
conference on harmonization (ICH) guidelines, Q1A-R2 in 
stability chamber (Durga Scientific Pvt. Ltd., Vadodara, 
India).Physical mixture powder was suspended in distilled 
water and solubilized drugwas filtered through Watman 
filter paper and estimated by UV Spectroscopy at 289 nm 
against distilled water as reference. 
Formulation of IER nanoparticles 
Ion Exchange Resin (IER) nanoparticles were prepared by 
Top down technique, wet milling[41,42,43,44,45,46,47] . Two types 
of Zirconium beads were used for the experiment: a) Cerium 
stabilized and b) Yttrium stabilized. IER suspension in 
distilled water was prepared and milled in a plastic bottle 
with the Zirconium beads on magnetic stirrer (Bio-Lab, 
Magnetic stirrer with hot plate, BL-223B, Vadodara, India) 
using teflon coated stir bar. Milling process parameters of all 
the IER nanoparticles batches are presented in Table 1. Batch 
size of IER nanopartricles was kept constant, 25 ml. At 
laboratory scale, milling time was fixed to 1 week (168 
hours) for all batches until all the process parameters were 
selected. Milling was carried out at room temperature, 20-
25°C. Volume based ratio of Zirconium beads quantity was 
used for IER milling. [Example of calculation: Bead quantity 
used for 25 ml batch size: 70% volume of Ce stabilized Zr 
beads = 12.5 ml = 68 gm (bulk density-3.9 gm/cc)]. After 
achieving nano size, IER nanoparticles, 25 ml (approx. 20% 
w/v concentration) were washed with distilled water to 
separate from Zirconium beads using 250 micron sieve 
[ASTM Mesh #60] and volume was made up to 100 ml to 
prepare approx. 5% w/v IER suspension. The IER 
nanoparticles suspension was stored in tightly closed 
containers for further characterization 
Characterization of IER nanoparticles 
Description:IER nanoparticles were collected to in 
transparent glass vials. Colour and physical appearance of 
samples of IER nanoparticles batch were noted by visual 
observation.
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Table 1: Effect of various milling process parameters on IER nanoparticles batches 
Batch no. 
IER 
(%) 
Type of Zr 
beads 
Zr bead 
size (mm) 
Zr bead 
volume 
(%) 
Milling time 
(hours) 
Description 
Sedimentation 
behaviour After 
48 hours 
NIER1 30 Ce stabilized 1.2-1.7 70 * Brown Susp. Not applicable 
NIER2 30 Ce stabilized 1.2-1.7 70 * Brown lumps Not applicable 
NIER3 20 Ce stabilized 1.2-1.7 70 168 Cream Susp. SedP 
NIER4 20 Ce stabilized 0.7-1.2 70 168 Cream Susp. SedP 
NIER5 20 Y stabilized 0.8 70 168 Cream Susp. SedP 
NIER6 20 Y stabilized 0.8 40 168 Cream Susp. SedP 
NIER7 20 Y stabilized 0.8 90 168 Cream Susp. SedP 
NIER8 20 Y stabilized 0.3 40 168 Cream Susp. SedP 
NIER9 
Part I 
20 
Y stabilized 0.8 40 72 Cream Susp. Not applicable 
Part II Y stabilized 0.3 40 96 Cream Susp. Non SedP 
NIER10 
Part I 
20 
Y stabilized 0.8 40 48 Cream Susp. Not applicable 
Part II Y stabilized 0.3 40 72 Cream Susp. Non SedP 
NIER11 
Part I 
20 
Y stabilized 0.8 40 48 Cream Susp. Not applicable 
Part II Y stabilized 0.3 40 48 Cream Susp. Non SedP 
NIER12 
Part I 
20 
Y stabilized 0.8 40 48 Cream Susp. Not applicable 
Part II Y stabilized 0.3 40 48 Cream Susp. Non SedP 
NIER13 
Part I 
20 
Y stabilized 0.8 40 48 Cream Susp. Not applicable 
Part II Y stabilized 0.3 40 48 Cream Susp. Non SedP 
*Inadequate Milling; SedP- Sedimenting Particles; Non SedP- Non Sedimenting Particles 
 
Sedimentation behaviour: Sedimentation behaviour was 
assessed by Sedimentation photograph capturing method 
over the period of specified time points[48,49,50]. IER 
nanoparticles batchsamples after completion of specified 
milling time (Table 1) were placed in transparent glass vials 
and photographs of sediment and supernant were captured 
after 8, 24 and 48 hours. Captured images of these time 
points were compared with photographs of 0 hours and 
Control sample i.e. unmilled IER suspension as well. 
Particle size and Polydispersity Index (PDI): The batch of 
optimized IER nanoparticles was estimated for particle size 
and Polydispersity Index (PDI) using Dynamic Light 
Scattering by Malvern Zeta sizer (Malvern Instruments Ltd, 
NanoZS, UK) after dilution with distilled water (1:1000). 
Zeta potential: The Zeta potential of batch of optimized IER 
nanoparticles was determined using Dynamic Light 
Scattering using Malvern Zetasizer after dilution with 
distilled water (1:1000). The sample was taken into small 
disposable zeta cell by taking care to avoid air bubble 
entrapment leading to the correct measurements. 
Formulation of MOX-IER nanoparticles 
Moxifloxacin Hydrochloride (MOX) and IER complex was 
prepared in various stoichiometric ratio (Table 2). Briefly, 
MOX was dissolved in distilled water at room temperature, 
20-25°C and added to IER suspension under stirring on 
Magnetic stirrer and stirring was continued for 30 min. 
Volume make was done up to batch size, 50 ml with distilled 
water.
 
Table 2: Composition of MOX-IER nanoparticles 
Batch Drug: Resin Ratio MOX (% w/w) IER (% w/w) 
MNIER1 1:0.2 0.5 0.1 
MNIER2 1:0.5 0.5 0.25 
MNIER3 1:1 0.5 0.5 
MNIER4 1:1.5 0.5 0.75 
MNIER5 1:2 0.5 1 
 Batch size - 50 ml 
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Characterization of MOX-IER nanoparticles 
Description: Samples of MOX-IER nanoparticles suspension 
were collected in transperant glass vials and colour and 
physical appearance were evaluated by visual observation. 
Entrapment efficiency: The amount of drug entrapped into 
IER nanoparticles was calculated using indirect method, by 
measuring unbound drug concentration[51]. Supernatant 
obatined after ultracentrifugation (Bio-Lab, Micro 
Centrifuge, BL-135, India) of MOX-IER nanoparticles at 
10,000 rpm for 75 min were filtered with Watman filter 
paper to get clear solution and thes same was analyzed by 
UV spectroscopy at 289 nm against distilled water.% 
Entrapment efficiency was calculated as per below equation. 
Entrapment Efficiency (%) = Initial drug – Free drug X100      (1) 
                                                               Initial drug 
pH: 5 ml of suspension was taken in a 10ml beaker and pH 
was recorded using calibrated pH meter (Chemi Line, Digital 
pH meter, CL-110, London, UK) by bringing a glass electrode 
near the surface of the formulation and allowing the 
equilibration for 1 min. 
Particle size and Polydispersity Index (PDI): The optimized 
batch of MOX-IER nanoparticles was estimated for particle 
size and Polydispersity Index (PDI) using Dynamic Light 
Scattering by Malvern Zeta sizer after dilution with distilled 
water (1:100). 
Zeta potential: The Zeta Potential of optimized batch of MOX-
IER nanoparticles batch was determined using Dynamic 
Light Scattering using Malvern Zetasizer after dilution with 
distilled water (1:100). The sample was taken into small 
disposable zeta cell by taking care to avoid air bubble 
entrapment leading to the correct measurements. 
In vitro release studies: In vitro release studyof MOX-IER 
nanoparticles and MOX solution as control was executed by 
dialysis bag method [52].Freshly prepared Simulated tear 
fluid (STF)containaing 0.67 g of Sodium chloride, 0.20 g of 
Sodium bicarbonate, 0.006 g of Calcium chloride dihydrate 
and 100 mL of deionised water[53] was used as dissolution 
media.1 gm of MOX-IER nanosuspension was filled in 12,000 
kDa molecular weight cut-off dialysis membrane (DM-70, Hi 
Media, Mumbai, India) after activation in alkaline solution. 
Both ends of the dialysis membrane were tied with thread 
and put in a beaker containing 100 ml dissolution media 
under stirring at 75 rpm on magnetic stirrer at 37 ± 0.5°C. At 
specified time points, 1ml of sample was withdrawn and 
sink condition was maintained with equal amount of fresh 
dissolution media. Withdrawn samples were centrifuged at 
10,000 rpm for 75 min and then filtered with Watman filter. 
The concentration of MOX was analysed in filtered samples 
by UV spectroscopy at 289 nm. Similary In vitro release of 
drug in distilled water was evaluated using same 
experimental conditions and time intervals. 
Statistical analysis: In vitro release study was performed for 
12 dosage units for each time point for validity of statistical 
analysis. Results are expressed as mean ± SEM. Two sample 
t-test was applied to analyse In vitro drug release data at 
95% Confidence Interval (CI) using Minitab®  18.1 (Minitab 
Inc., Pennsylvania, USA). 
RESULTS AND DISCUSSION 
Drug characterization 
Solubility:Solubility of Moxifloxacin Hydrochloride was 
found to be 1 g in 60 ml distilled water (approx. 16 mg/ml) 
at room temperature, 20-25°C which is sparingly soluble as 
per USP solubility classification, 1 part in 30 to 100 parts of 
solvent. 
Spectrophotometric analysis: Maximum absorbance of 0.818 
was noted at maximum wavelength 289 nm in distilled 
water which is supported by literature[54]. At 289 nm, linear 
curve of  2, 4, 6, 8, 10 ppm Moxifloxacin Hydrochloride 
solution in distilled water was prepared with regression 
coefficient, r2 of 0.992 (calculated using Microsoft Excel, 
Windows® 2013) reflecting linearity of the plot. From the 
calculated linear equation y = mx + c, concentration of MOX 
in all the samples was determined. 
Drug-IER compatibility 
No significant difference was noted in MOX content in the 
physical mixture of Drug and IER before and after incubation 
of 1 month accelerated stability, 99.47% w/v and 98.62% 
w/v respectively. 
Formulation of IER nanoparticles 
Apparently during preparation of nanoparticles, as the 
particle size is decreased change in colour is observed e.g. 
gold nanoparticles change their colour from blue to red[55]. 
Studies also have been carried out to observe effect of 
particle size reduction on optical properties and colour 
change of pigments prepared by grinding [56]. Nano sized 
particles merely do not settle in the dispersion and micron 
sized particles settle quickly with respect to time[57]. Milling 
process parameters for preparation of IER nanoparticles 
were optimized considering these two characterizations: (a) 
Description: colour change (brown to cream) (b) 
Sedimentation behaviour: non sedimenting particles. (Table 
1). Milling process parameters were for optimized based on 
OFAT approach, One Factor at a Time [58]. 
Suitable container for milling was found to be HDPE bottle 
considering inefficient milling in LDPE bottle because the 
latter was unable to bear the load of highly dense Zr beads 
(NIER1). 20% concentration of IER at laboratory scale of 25 
ml was found to be appropriate considering lumps 
formation at higher concentration and feasibility (NIER2 and 
NIER3). Since particle size reduction was observed in similar 
fashion with Yttrium stabilized Zr beads and Cerium 
stabilized Zr beads considering higher mechanical strength 
of former, Yttrium stabilized Zr beads were selected for 
further milling batches (NIER3, NIER4 and NIER5). Yttrium 
stabilized Zr beads are most inert media used in 
pharmaceuticals as they do not interact with drug and avoid 
incorporation of impurities in the formulation[59]. Since 
there was no significant change in description of samples of 
IER nanoparticles at various bead volume ratios, 40% bead 
volume was selected for further milling batches. (NIER5, 
NIER6, NIER7) 
Bead size selection was done with the support of extensive 
literature and characterization of IER nanoparticles batches. 
For instance, various IER nanoparticles batches were 
prepared by keeping aforementioned selected process 
parameters constant and varying bead size & combinations. 
As per literature pertaining to milling technology [60,61,62] 
bead size should be approximately 10x smaller than input 
material particle size or approximately 1000x larger than 
desired particle size. So, for IER milling, ideal bead sizes can 
be 0.5 mm (considering target desired nano size 500 nm) or 
0.75 mm to 1.5 mm [considering IER input particle size 75-
150 micron (Product Data sheet, 2016)]. Preparing IER 
nanoparticles batches using bead size in the mentioned 
range (NIER1 to NIER8) showed sedimenting particles in the 
samples, hence could not achieve nano sized particles. The 
particle size reduction effect could be enhanced by using 
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smaller bead size[63]. Therefore combination approach was 
tried using two sized beads: milling of IER suspension by 
larger sized beads (0.8 mm) followed by smaller sized beads 
(0.3 mm) which yielded nanosized particles (NIER9). Then 
after efforts were made to reduce milling time with 
combined bead sizes and as a result, nanosized particles 
were obtained after 96 hours evident by two consistent 
batches with non sedimenting particles (NIER11 and 
NIER12) and particle size reports of optimized batch 
(NIER13). 
Characterization of IER nanoparticles 
Description: Colour and physical appearance of the IER 
samples was found to be brown and suspension form when 
particle size is not reduced and the same was cream 
suspension for the samples where particle size was reduced 
from raw resin (Table 1). 
 
 
Figure 1: Sedimentation behaviour: Left vial, Control – Unmilled IER Susp., Right vial – NIER8, Sedimenting particles in IER 
Susp. 
 
Sedimentation behaviour: Sedimentation behaviour of all IER 
nanoparticles batches is presented in Table 1. Literature 
reveals that suspended particles in the dispersion with 
higher particle size settle at higher rate than that of lower 
particle size[64]. The same was evident in current 
experiment.IER nanoparticles with higher particle size 
settled significantly (Figure 1, representative batch NIER8) 
and nanosized particles did not settle (Figure 2, 
representative batch NIER9) over the period of 48 hours 
when compared with unmilled Ion Exchange Resin 
suspension.
 
 
Figure 2:  Sedimentation behaviour: Left vial, Control – Unmilled IER Susp., Right vial – NIER9, Non sedimenting particles in IER 
Susp. 
 
Particle size and Polydispersity Index (PDI): Particle size of 
optimized IER nanoparticles batch, NIER13 was found to be 
360 nm (Figure 3) reflecting smaller nanosized particles. 
Lesser PDI i.e. 0.221 proved that prepared nanoparticles 
have uniform and narrow size distribution[65].
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Figure 3: Particle size distribution study of optimized IER nanoparticles batch NIER13 
 
Zeta potential: Nanoparticle surface charge (Zeta Potential) 
of optimized batch, NIER13 (Figure 4) was estimated to - 
41.3 mV reflecting good physical stability of the suspension. 
Higher value of Zeta pontential in positive or negative side 
preferably above +30 mV or -30 mV indicates stable 
nanosuspension when kept in storage for long time because 
of very low or no chances of aggregation between the 
nanosized particles [66].Negative values of Zeta potential 
reflects anionic chemical nature of IER, Sodium polystyrene 
sulfonate due to presence of SO3- functional group.
 
 
Figure 4: Zeta potential study for optimized IER nanoparticles batch NIER13 
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Formulation of MOX-IER nanoparticles 
Moxifloxacin bears cationic charge due to presence of 
tertiary amine functional groups. Sodium polystyrene 
sulfonate which is a strong cation exchange resin bears 
anionic charge due to presence of sulfonate functional group 
on to styrene divinyl benzene backbone. Both form an ionic 
complex. Structures are presented in Figure 5 (a,b). MOXand 
IER stoichiometric ratio was decided considering theresults 
of Entrapment efficiency. 
 
  
Figure 5: Chemical structures (a) Moxifloxacin HCl, (b) IER Sodium polystyrene sulfonate 
 
Characterization of MOX-IER nanoparticles 
Description: Colour and physical appearance of the MOX-IER 
nanoparticles samples was found to be cream suspension. 
Entrapment Efficiency: MOX-IER stoichiometric ratio 
optimization was critically carried out on the basis of 
Entrapment Efficiency. From the Graphical presentation 
(Figure 6) it was observed that MOX-IER ratio was inversely 
proportional to %EE up to definite concentration of resin. 
Based on Entrapment Efficiency results 81% to 95%, highest 
EE was achieved with Drug resin ratio 1:1, 1:1.5 and 1:2. 
Amongst 1:1 Drug resin ratio was chosen with the fact that 
highest EE could be achieved without using very high 
concentration of IER. 
 
 
 
Figure 6: Entrapment efficiency of MOX-IER nanoparticles 
 
pH: pH of Moxifloxacin HCl was 4.66 reflecting cationic 
nature of the drug. pH of MOX-IER nanoparticles was in the 
range of 5.6 to 6.0. The same was measured to be 5.74 the 
optimized batch, MNIER3 which is moving towards neutral 
reflecting ionic complexation from drug solution pH. 
Particle size and Polydispersity Index (PDI): Particle size 
distribution result (Figure 7) of MNIER3, 301 nm and lesser 
PDI i.e. 0.215 was an evident that Resin nanoparticles 
remained non aggregated uniform suspended particles after 
Moxifloxacin entrapment. 
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Zeta potential 
 
Figure 7: Particle size distribution study of optimized MOX-IER nanoparticles batch MNIER3 
 
Zeta Potential: Nanoparticle surface charge of Drug loaded 
Resin Nanoparticles optimized batch, MNIER3 was estimated 
to - 37.8 mV (Figure 8) reflects that the suspension retained 
physical stability after entrapment with Moxifloxacin.  
In vitro release studies: Cumulative drug release (CDR) of 
MOX was compared as a mean of 12 units of MOX-IER 
nanoparticles and MOX aqueous solution (Figure 9). MOX 
was released faster in aqueous solution than nanoparticles 
form. Approx. 95% of drug was released from MOX aqueous 
solution in just 1 hour and the same took 4 hours from MOX-
IER nanoparticles which apparently indicate the sustained 
release of Moxifloxacin from drug-resin complex (MOX-IER) 
nanoparticles. 
 
 
Figure 8: Zeta potential study of optimized MOX-IER nanoparticles batch MNIER3 
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Figure 9: In vitro drug release of MOX-IER Nanoparticles batch MNIER3 
Various mathematical models were applied to understand 
drug release kinetics like Zero-order, First order, Higuchi 
and Korsmeyer –Peppas[68,69].Graphical presentation is 
depicted in Figure10 and Linear regression analysis is 
summarized in Table 3.Based on Correlation Coefficient (r2) 
value 0.912, Korsmeyer-Peppas model was considered to be 
the best fit model MOX-IER nanoparticles.  
 
 
 
Figure 10: Drug release kinetic models of MOX-IER Nanoparticles batch MNIER3 
 
The value of release exponent n in Korsmeyer-Peppasmodel 
indicate mechanism of drug release:0.5 indicates Fickian 
diffusion, between 0.45 and 0.89 indicates Non -Fickian 
transport, 0.89 indicatesZero order release and n value higher 
than 0.89 indicates Super case II transport mechanism. n value 
of 0.4387 for MOX-IER nanoparticles reveals that drug release 
is diffusion controlled (Fickian diffusion). 
 
Statistical analysis 
Table 3: Drug release kinetics models 
Drug release Kinetics model Equation r2 
Zero-order y = 8.9517x + 42.554 0.692 
First order y = 0.0691x + 1.5717 0.550 
Higuchi y = 32.741x + 19.712 0.851 
Korsmeyer-Peppas y = 1.6908x 0.4387  0.912 
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Significant difference in % CDR at each time point was 
observed based on two sample t-test results at p value <0.05 
using Minitab®  18.1between MOX aqueous solution and 
MOX-IER nanoparticles. 
CONCLUSION 
Developed MOX-IER nanoparticles in form of nanosuspension 
was a physically stable formulation with uniform particle size 
distribution providing high entrapment efficiency and showed 
sustained drug release behaviour in simulated tear fluid. 
These qualities make this formulation suitable for ocular 
delivery system. 
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